Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2001

01-08-2001

A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer

Authors: Nicholas J. Vogelzang, Mebea Aklilu, Walter M. Stadler, Mary C. Dumas, Stanislaw M. Mikulski

Published in: Investigational New Drugs | Issue 3/2001

Login to get access
Metadata
Title
A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer
Authors
Nicholas J. Vogelzang
Mebea Aklilu
Walter M. Stadler
Mary C. Dumas
Stanislaw M. Mikulski
Publication date
01-08-2001
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2001
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1010633004157

Other articles of this Issue 3/2001

Investigational New Drugs 3/2001 Go to the issue

OriginalPaper

Tetramethylpiperidine-Substituted Phenazines Inhibit the Proliferation of Intrinsically Multidrug Resistant Carcinoma Cell Lines

OriginalPaper

Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer

OriginalPaper

Altretamine for the Treatment of Metastatic Renal Cell Carcinoma – A Hoosier Oncology Group Trial

OriginalPaper

Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study

OriginalPaper

Phase II Trial of GM-CSF in Advanced Prostate Cancer

OriginalPaper

Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits